Treatment of idiopathic pulmonary fibrosis

By administering AK3280 or its pharmaceutically acceptable salts, the problems of poor efficacy and severe side effects of existing idiopathic pulmonary fibrosis treatments have been resolved, resulting in improved respiratory function and reduced side effects, providing a more effective and well-tolerated treatment option.

WO2026238003A1PCT designated stage Publication Date: 2026-11-19SHANGHAI ARK BIOSCI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096733
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-13
Filing Date
2026-05-13
Publication Date
2026-11-19

Smart Images

  • Figure CN2026096733_19112026_PF_FP_ABST
    Figure CN2026096733_19112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to a use and a dosage regimen of compound I in the treatment of idiopathic pulmonary fibrosis. Specifically, the present disclosure relates to the use of compound I in the treatment of idiopathic pulmonary fibrosis, which can achieve an absolute increase in FVC after 24 weeks of treatment without presenting tolerance issues such as gastrointestinal discomfort caused by existing IPF medications.
Need to check novelty before this filing date? Find Prior Art

Description

Treatment of idiopathic pulmonary fibrosis

[0001] This application claims priority to Chinese patent application 2025106132568, filed on May 13, 2025. The entire contents of the aforementioned Chinese patent application are incorporated herein by reference. Technical Field

[0002] This invention relates to the field of idiopathic pulmonary fibrosis treatment technology, and in particular, to a treatment regimen for idiopathic pulmonary fibrosis using compound I. Background Technology

[0003] Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible lung disease of unknown cause, characterized by continuous damage and fibrosis of lung tissue, leading to progressive deterioration of lung function. IPF is more common in people over 60 years of age, and its main symptoms include dry cough, progressive dyspnea that worsens with activity, and end-inspiratory crackles heard on lung auscultation. Clubbing of the fingers (toes) is observed in more than half of the patients. In the end stage, signs of cyanosis, pulmonary hypertension, cor pulmonale, and right heart failure may appear. IPF has a poor prognosis, with a median survival of only 2 to 5 years after diagnosis. Approximately 5% to 20% of patients experience acute exacerbations during the course of the disease. The median survival for acute exacerbations of IPF is only 2 to 3 months, and the in-hospital mortality rate exceeds 60%. Progression of IPF leads to worsening pulmonary fibrosis, decreased forced vital capacity (FVC) and gas exchange function (i.e., pulmonary carbon monoxide diffusing capacity (DLCO)), decreased exercise capacity, deteriorating quality of life, worsening cough and dyspnea, and acute exacerbations (Cottin et al., Eur Respir Rev. 2019 Feb 27; 28(151)). Among these, decreased forced vital capacity (FVC) is a predictor of mortality in IPF patients and has been used as a clinical trial endpoint to define disease progression.

[0004] Treatment for IPF primarily focuses on slowing disease progression, alleviating symptoms, and preventing complications. Current treatment options include medication, oxygen therapy, pulmonary rehabilitation, and lung transplantation. Only pirfenidone (PFD) and nintedanib are approved for antifibrotic treatment of IPF. However, neither of these drugs can stop or reverse disease progression, and up to one-third of patients cannot tolerate them after six months of treatment (M. Senior, Fighting fibrosis, Nat. Biotechnol. 40(8)(2022) 1169–1173). Pirfenidone is a small molecule drug that has been shown to have various anti-inflammatory and antifibrotic effects, and can significantly slow the decline in forced vital capacity (FVC). However, gastrointestinal and skin-related adverse events, including anorexia, nausea, vomiting, and photosensitive rashes, may lead patients to discontinue treatment (TEKing, WZ Bradford, S. Castro-Bernardini, EA Fagan, I. Glaspole, MK Glassberg, E. Gorina, PM Hopkins, D. Kardatzke, L. Lancaster, DJ Lederer, SD Nathan, CAPereira, SASahn, R. Sussman, JJ Wigris, PW Noble, AS Group, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, N. Engl. J. Med. 370(22)(2014) 2083–2092.). Nintedanib is a potent oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor. Clinical trials have shown that nintedanib can slow the decline in forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (HYYoon, S. Park, DSKim, JWSong, Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis, Respir. Res. 19(1)(2018) 203.).However, nausea and diarrhea are the most common side effects of nintedanib, and serious adverse events have been reported in approximately 30% of patients treated with nintedanib (M. Kato, S. Sasaki, T. Nakamura, K. Kurokawa, T. Yamada, Y. Ochi, H. Ihara, F. Takahashi, K. Takahashi, Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis, Sci. Rep. 9(1)(2019) 12062.). Therefore, pirfenidone and nintedanib are only recommended for IPF patients with mild to moderate FVC impairment (≥50% predictive value).

[0005] Besides pirfenidone and nintedanib, many other IPF treatments are still under development, such as BI 1015550, BMS-986278, ARO-MMP7, Buloxibutid, AK3280, Zelasudil, Taladegib, and INS018_055. Summary of the Invention

[0006] AK3280 is a new generation of broad-spectrum anti-fibrotic molecule that can regulate the expression of multiple pathways and biomarkers closely related to the pathological process of fibrosis, including fibrosis-related genes and proteins induced by transforming growth factor-β (TGF-β) and lysophosphatidic acid (LPA), reduce cell proliferation, and inhibit the synthesis and aggregation of extracellular matrix.

[0007] This invention provides the use of AK3280 or a pharmaceutically acceptable salt thereof in the preparation of medicaments for treating idiopathic pulmonary fibrosis (IPF) and methods for treating IPF. The medicaments or methods of this invention exhibit better tolerability in treating IPF and have the potential to reverse IPF progression.

[0008] Solution for solving the problem

[0009] In one aspect, a method for treating idiopathic pulmonary fibrosis is provided, comprising administering to a person in need a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof, wherein the total daily dose of compound I is 200-1000 mg;

[0010] For example, the total daily dose of compound I is 200-900 mg, 200-800 mg, 300-1000 mg, 300-900 mg, 300-800 mg, 400-1000 mg, 400-900 mg, 400-800 mg, 500-1000 mg, 500-900 mg, 500-800 mg, 600-1000 mg, 600-900 mg, 600-800 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg. Preferably, the total daily dose is 200-800 mg, more preferably 400-800 mg, and even more preferably 600-800 mg.

[0011] For example, the pharmaceutical composition can be administered intravenously, orally, rectally, or sublingually.

[0012] For example, the route of administration of the pharmaceutical composition is oral.

[0013] For example, the route of administration of the pharmaceutical composition is intravenous injection.

[0014] For example, the route of administration of the pharmaceutical composition is rectal administration.

[0015] For example, the route of administration of the pharmaceutical composition is sublingual.

[0016] Preferably, the total daily dose is administered once, twice, or three times a day, preferably twice a day.

[0017] Preferably, the total daily dose is 600 or 800 mg, administered in two equal doses.

[0018] For example, the total daily dose is 600 mg, administered in two equal doses.

[0019] For example, the total daily dose is 800 mg, administered in two equal doses.

[0020] Preferably, the duration of administration of the total daily dose includes a first treatment period and / or a second treatment period.

[0021] For example, the duration of administration of the total daily dose includes the first treatment period.

[0022] For example, the duration of administration of the total daily dose includes a first treatment period and a second treatment period.

[0023] Preferably, the first treatment period is at least 24 weeks, or for example at least 12 weeks, at least 48 weeks, at least 52 weeks, at least 104 weeks, or for life if necessary.

[0024] Preferably, the second treatment period is at least 24 weeks, or for example at least 12 weeks, at least 48 weeks, at least 52 weeks, at least 104 weeks, or for life if needed.

[0025] Preferably, the treatment for idiopathic pulmonary fibrosis (IPF) includes administration of a total daily dose selected from the group consisting of 200 mg, 400 mg, 600 mg, and 800 mg during the first treatment period.

[0026] Preferably, the idiopathic pulmonary fibrosis (IPF) treatment method includes administration of a total daily dose selected from the group consisting of 400 mg, 600 mg, and 800 mg during the second treatment period.

[0027] Preferably, the person in need is an adult aged 40-80.

[0028] Preferably, the dosage form of the pharmaceutical composition is tablets, hard capsules, soft capsules, oral solutions, drop pills, granules, or sustained-release microcapsules, preferably tablets.

[0029] Preferably, the dosage form of the pharmaceutical composition is a powder, pill, tablet, capsule, oral liquid, aerosol, or injection.

[0030] For example, the dosage form of the pharmaceutical composition is a nano-suspension tablet.

[0031] Preferably, the idiopathic pulmonary fibrosis (IPF) treatment method reverses, prevents, delays, or slows down respiratory impairment or the progression of IPF in the patient in need.

[0032] For example, the treatment method reverses respiratory dysfunction or the progression of IPF in the patient in need.

[0033] For example, the treatment method can delay or slow the progression of respiratory impairment or IPF in the patient in need.

[0034] For example, the treatment method reverses the progression of respiratory dysfunction in the person in need.

[0035] Preferably, the progression of respiratory function impairment is determined by measuring changes in forced vital capacity and / or percentage-predicted forced vital capacity (%pFVC) during the first and / or second treatment periods.

[0036] For example, the progression of the respiratory function impairment was determined by measuring changes in forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) during the first 24-week treatment period.

[0037] For example, the progression of the respiratory function impairment was determined by measuring changes in forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) during the first and second 24-week treatment periods.

[0038] For example, the treatment period used to measure changes in FVC and / or %pFVC is from baseline to a treatment period selected from the following: at least 24 weeks, at least 48 weeks, at least 52 weeks, or at least 104 weeks.

[0039] For example, the treatment period for measuring changes in FVC and / or %pFVC is at least 24 weeks.

[0040] For example, measure changes in FVC and / or %pFVC from baseline to at least 24 weeks of treatment.

[0041] For example, the treatment period for measuring changes in FVC and / or %pFVC is at least 48 weeks.

[0042] For example, measure changes in FVC and / or %pFVC from baseline to at least 52 weeks of treatment.

[0043] Preferably, compared to before treatment, the idiopathic pulmonary fibrosis (IPF) treatment method improves at least one symptom selected from the group consisting of: forced vital capacity (FVC), percentage predicted forced vital capacity (%pFVC), carbon monoxide diffusion capacity (DLco), St. George's Respiratory Questionnaire score (SGRQ), and 6-minute walk test distance (6MWT).

[0044] For example, compared to before treatment, the method improved forced vital capacity (FVC), %pFVC, carbon monoxide diffusion capacity (DLco), St. George's Respiratory Questionnaire score (SGRQ), and 6-minute walk test distance (6MWT).

[0045] Preferably, during the first treatment period of at least 24 weeks, the idiopathic pulmonary fibrosis (IPF) treatment method increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) compared to before treatment.

[0046] Preferably, during the first treatment period of at least 24 weeks, the idiopathic pulmonary fibrosis (IPF) treatment method increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) by administering a total daily dose of 800 mg compared to before treatment.

[0047] Preferably, the method increases the %pFVC value by at least 2%, more preferably at least 4%, and more preferably at least 6%.

[0048] For example, during the first treatment period of 24 weeks, compared to before treatment, with a total daily dose of 800 mg, the percentage increase in forced vital capacity by the method was 1%-7%, 2%-6.5%, 3%-7%, 4%-6.5%, 5%-7%, 5%-6.5%, 3%, 4%, 5%, 6%, 6.4%, 6.5%, and 7%.

[0049] Preferably, during the first treatment period of 24 weeks, the method increases the %pFVC by 6.4% compared to the total daily dose of 800 mg before treatment.

[0050] Preferably, during the first treatment period of at least 24 weeks, the idiopathic pulmonary fibrosis (IPF) treatment method increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) by administering a total daily dose of 600 mg compared to before treatment.

[0051] Preferably, the method increases the %pFVC value by at least 1%, more preferably at least 2%, and more preferably at least 3%.

[0052] For example, during the first 24-week treatment period, compared to before treatment, when a total daily dose of 600 mg was administered, the increase in %pFVC by the method was 1%-4%, 1.5%-4%, 2%-4%, 2.5%-4%, 3%-4%, 1%-3.5%, 1.5-3.5%, 2%-3.5%, 2.5%-3.5%, 3%-3.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.3%, 3.5%, and 4%.

[0053] Preferably, during the first treatment period of 24 weeks, the method increases the %pFVC by 3.3% compared to the pre-treatment total daily dose of 600 mg.

[0054] Preferably, during the first treatment period of at least 12 weeks, the idiopathic pulmonary fibrosis (IPF) treatment method reduces the St. George's Respiratory Questionnaire (SGRQ) score compared to before treatment.

[0055] Preferably, during the first treatment period of at least 12 weeks, the St. George's Respiratory Questionnaire (SGRQ) score of the idiopathic pulmonary fibrosis treatment method is reduced by at least 2 points, preferably at least 3 points, and more preferably at least 4 points, compared to before treatment, when a total daily dose of 800 mg is administered.

[0056] Preferably, during the first treatment period of at least 24 weeks, the idiopathic pulmonary fibrosis (IPF) treatment method reduces the St. George's Respiratory Questionnaire (SGRQ) score compared to before treatment.

[0057] Preferably, during the first treatment period of at least 24 weeks, the St. George's Respiratory Questionnaire (SGRQ) score of the idiopathic pulmonary fibrosis treatment method is reduced by at least 4 points, preferably at least 5 points, and more preferably at least 6 points, compared to before treatment, when a total daily dose of 800 mg is administered.

[0058] Preferably, during the first treatment period of at least 24 weeks, the idiopathic pulmonary fibrosis (IPF) treatment method reduces the proportion of 6MWT worsening compared to before treatment, and preferably, the method reduces the proportion of 6MWT decline by more than 50m.

[0059] Preferably, during the first treatment period of at least 24 weeks, a total daily dose of 600 mg is administered, and the proportion of idiopathic pulmonary fibrosis (IPF) treatment that reduces 6MWT by more than 50 m compared to before treatment is reduced to less than 20%, preferably less than 18%, more preferably less than 17%.

[0060] Preferably, during the first treatment period of at least 24 weeks, a total daily dose of 800 mg is administered, and the proportion of idiopathic pulmonary fibrosis (IPF) treatment method that reduces 6MWT by more than 50 m compared to before treatment is less than 15%, preferably less than 12%, more preferably less than 10%.

[0061] Preferably, the idiopathic pulmonary fibrosis (IPF) treatment method exhibits a reduction in at least one adverse event selected from the group consisting of: rash, photosensitivity, nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, loss of appetite, constipation, headache, dizziness, somnolence, fatigue, drug intolerance, elevated AST, ALT, GGT, and hepatotoxicity.

[0062] Preferably, the idiopathic pulmonary fibrosis (IPF) treatment method exhibits a reduction in at least one gastrointestinal-related adverse event selected from the group consisting of: nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, decreased appetite, and constipation.

[0063] Preferably, the idiopathic pulmonary fibrosis (IPF) treatment method exhibits a reduction in at least one neurological-related adverse event selected from the group consisting of headache, dizziness, and somnolence.

[0064] Preferably, the idiopathic pulmonary fibrosis (IPF) treatment method exhibits a reduction in at least one liver function-related adverse event selected from the group consisting of elevated AST, ALT, GGT, and hepatotoxicity.

[0065] Preferably, the idiopathic pulmonary fibrosis (IPF) method exhibits a reduction in at least one skin-related adverse event selected from the group consisting of rash and photosensitivity.

[0066] Preferably, the method exhibits a reduced increase in GGT.

[0067] Preferably, the method exhibits a reduction in gastrointestinal adverse events (including diarrhea, indigestion, nausea, bloating, flatulence, etc.).

[0068] Preferably, the method results in reduced diarrhea.

[0069] Preferably, the patient in need meets the conditions of %FVC≥50% and ≤90% and %DLco≥30% and ≤90% before starting treatment.

[0070] Preferably, the patient in need has not received prior treatment for idiopathic pulmonary fibrosis (IPF).

[0071] For example, the person in need has not previously received treatment with nintedanib and / or pirfenidone.

[0072] For example, the person in need has not previously received treatment with nintedanib and pirfenidone.

[0073] Preferably, the patient in need has received prior treatment for idiopathic pulmonary fibrosis (IPF).

[0074] For example, the patient in need has previously received treatment with nintedanib and / or pirfenidone.

[0075] Preferably, the pharmaceutical composition is administered orally.

[0076] Preferably, the compound as shown in Formula I or a pharmaceutically acceptable salt thereof is one or the only active ingredient of the pharmaceutical composition.

[0077] Preferably, the prior treatment for idiopathic pulmonary fibrosis (IPF) is nintedanib and / or pirfenidone.

[0078] In one aspect, the use of compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating idiopathic pulmonary fibrosis is provided;

[0079] Preferably, the drug comprises compound I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

[0080] Preferably, the excipients include one or more of the following: fillers, excipients, stabilizers, diluents, binders, disintegrants, lubricants, flow aids, wetting agents, effervescent agents, colorants, sweeteners, flavorings, preservatives, dispersants, film-forming agents, plasticizers, pore-forming agents, light-blocking agents, retardants, and solvents.

[0081] Preferably, the drug comprises a free base of compound I. Preferably, the dosage form of the drug is a powder, pill, tablet, capsule, oral liquid, aerosol, or injection, preferably a tablet.

[0082] Preferably, the drug contains 100 mg of compound I.

[0083] Preferably, the total daily dose of compound I is 200-1000 mg.

[0084] Preferably, the total daily dose of compound I is 200-800 mg, more preferably 400-800 mg, and even more preferably 600-800 mg.

[0085] Preferably, the total daily dose is administered once, twice, or three times a day, preferably twice a day.

[0086] Preferably, the total daily dose is 600 or 800 mg, administered in two equal doses.

[0087] Preferably, the duration of administration of the total daily dose includes a first treatment period and / or a second treatment period.

[0088] Preferably, the first treatment period is at least 24 weeks, or for example, at least 12 weeks.

[0089] Preferably, the second treatment period is at least 24 weeks, or for example, at least 12 weeks.

[0090] Preferably, compound I is administered during the first treatment period at a total daily dose selected from the group consisting of 200 mg, 400 mg, 600 mg, and 800 mg.

[0091] Preferably, compound I is administered during the second treatment period at a total daily dose selected from the group consisting of 400 mg, 600 mg, and 800 mg.

[0092] Preferably, the drug is administered to adults aged 40-80.

[0093] Preferably, the drug is a powder, pill, tablet, capsule, oral liquid, aerosol, or injection, and preferably a tablet.

[0094] Preferably, the drug is a tablet, hard capsule, soft capsule, oral solution, drop pill, granule, or sustained-release microcapsule, and preferably a tablet.

[0095] Preferably, the application is capable of reversing, preventing, delaying, or slowing the progression of respiratory impairment in the person in need.

[0096] Preferably, the progression of respiratory function impairment is determined by measuring changes in forced vital capacity and / or percentage-predicted forced vital capacity (%pFVC) during the first and / or second treatment periods.

[0097] Preferably, compared to before treatment, the application improves at least one symptom selected from the group consisting of: forced vital capacity (FVC), percentage predicted forced vital capacity (%pFVC), carbon monoxide diffusing capacity (DLco), St. George's Respiratory Questionnaire score (SGRQ), and 6-minute walk test distance (6MWT).

[0098] Preferably, during the first treatment period of at least 24 weeks, the application increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) compared to before treatment.

[0099] Preferably, during the first treatment period of at least 24 weeks, a total daily dose of 800 mg is administered compared to before treatment, and the application increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC).

[0100] Preferably, the increase in %pFVC by the application is at least 2%, more preferably at least 4%, and more preferably at least 6%.

[0101] Preferably, during the first treatment period of at least 24 weeks, a total daily dose of 600 mg is administered compared to before treatment, and the application increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC).

[0102] Preferably, the increase in %pFVC by the application is at least 1%, more preferably at least 2%, and more preferably at least 3%.

[0103] Preferably, during the first treatment period of at least 12 weeks, the application reduces the St. George Respiratory Questionnaire (SGRQ) score compared to before treatment.

[0104] Preferably, during the first treatment period of at least 12 weeks, with a total daily dose of 800 mg compared to before treatment, the application resulted in a reduction of at least 2 points in the St. George Respiratory Questionnaire (SGRQ) score, preferably at least 3 points, and more preferably at least 4 points.

[0105] Preferably, during the first treatment period of at least 24 weeks, the application reduces the St. George Respiratory Questionnaire (SGRQ) score compared to before treatment.

[0106] Preferably, during the first treatment period of at least 24 weeks, the application of a total daily dose of 800 mg, compared to before treatment, resulted in a reduction of at least 4 points in the St. George Respiratory Questionnaire (SGRQ) score, preferably at least 5 points, and more preferably at least 6 points.

[0107] Preferably, during the first treatment period of at least 24 weeks, the application reduces the rate of 6MWT deterioration compared to before treatment; more preferably, the application reduces the rate of 6MWT decline by more than 50m.

[0108] Preferably, during the first treatment period of at least 24 weeks, a total daily dose of 600 mg is administered, and the application reduces the proportion of 6MWT decrease by more than 50 m compared to before treatment by less than 20%, preferably less than 18%, and more preferably less than 17%.

[0109] Preferably, during the first treatment period of at least 24 weeks, a total daily dose of 800 mg is administered, and the application reduces the proportion of 6MWT decrease by more than 50m to less than 15%, preferably less than 12%, more preferably less than 10%, compared to before treatment.

[0110] Preferably, the application exhibits a reduction in at least one adverse event selected from the group consisting of: rash, photosensitivity, nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, loss of appetite, constipation, headache, dizziness, drowsiness, fatigue, drug intolerance, elevated AST, ALT, GGT, and hepatotoxicity.

[0111] Preferably, the application exhibits a reduction in at least one gastrointestinal-related adverse event selected from the group consisting of nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, decreased appetite, and constipation.

[0112] Preferably, the application exhibits a reduction in at least one neurological-related adverse event selected from the group consisting of headache, dizziness, and drowsiness.

[0113] Preferably, the application exhibits a reduction in at least one liver function-related adverse event selected from the group consisting of elevated AST, ALT, GGT, and hepatotoxicity.

[0114] Preferably, the application exhibits a reduction in at least one skin-related adverse event selected from the group consisting of: rash and photosensitivity.

[0115] Preferably, the application exhibits a reduced increase in GGT.

[0116] Preferably, the application exhibits a reduction in gastrointestinal adverse events (including diarrhea, indigestion, nausea, bloating, flatulence, etc.).

[0117] Preferably, the application results in reduced diarrhea.

[0118] Preferably, the subjects of the application meet the conditions of %FVC≥50% and ≤90% and %DLco≥30% and ≤90% before the start of treatment.

[0119] Preferably, the subject of the application has not received prior treatment for IPF.

[0120] Preferably, the subject of the application has received prior treatment for IPF.

[0121] Preferably, the prior treatment for IPF is nintedanib and / or pirfenidone.

[0122] Preferably, the drug is administered orally.

[0123] Preferably, the compound as shown in Formula I or its pharmaceutically acceptable salt is one or the only active ingredient of the drug.

[0124] Preferably, among drug-related adverse events occurring in ≥10% of any treatment group up to 24 weeks of treatment, the following events accounted for 8.4% of all adverse events: rash, 8.4% of elevated aspartate aminotransferase, 8.4% of elevated alanine aminotransferase, 8.4% of decreased platelet count, 8.4% of decreased glomerular filtration rate, 6.0% of elevated serum creatine phosphokinase, 6.0% of elevated gamma-glutamyl transferase, 3.6% of elevated urinary β2-microglobulin, and 2.4% of diarrhea.

[0125] Preferably, among drug-related treatment-related adverse events occurring in ≥10% of any treatment group up to 24 weeks of treatment, the overall incidence of treatment-related gastrointestinal disorders (including diarrhea, indigestion, nausea, bloating, flatulence, etc.) related to compound I was 13.3%.

[0126] Preferably, the incidence of associated rashes or photosensitivity of compound I is less than 8.4%.

[0127] Preferably, the incidence of adverse gastrointestinal reactions related to compound I is less than 13.3%.

[0128] Preferably, the incidence of elevated γ-glutamyltransferase associated with compound I is less than 6.0%.

[0129] In another aspect, the use of compound I or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating interstitial lung disease (PF-ILD) is provided, comprising administering to a person in need a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof, wherein the total daily dose of said compound I is 200-1000 mg.

[0130] Preferably, the interstitial lung disease includes non-progressive fibrotic interstitial lung disease and progressive fibrotic interstitial lung disease.

[0131] Preferably, the progressive fibrotic interstitial lung disease is, for example, idiopathic pulmonary fibrosis.

[0132] Preferably, the progressive fibrotic interstitial lung disease is, for example, PPF.

[0133] Preferably, the non-progressive fibrotic interstitial lung disease is, for example, hypersensitivity pneumonitis or non-fibrotic NSIP (nonspecific interstitial pneumonia).

[0134] Preferably, the total daily dose, administration method, recipient, dosage form, treatment period, and symptom improvement of the pharmaceutical composition are the same as those described in the previous two aspects.

[0135] The effects of the invention

[0136] Compared to previous antifibrotic drugs that primarily aimed to slow the decline in free venous capillary (FVC), AK3280, especially the high-dose group, achieved an absolute increase in FVC within 24 weeks, reversing the decline in FVC, and other respiratory function indicators also improved to varying degrees. Furthermore, AK3280 demonstrated good tolerability and safety across all dosage groups, significantly reducing the gastrointestinal adverse reactions associated with previous antifibrotic drugs. These findings confirm that AK3280 is a promising treatment for IPF. Attached Figure Description

[0137] Figure 1 shows the chemical structure of AK3280.

[0138] Figure 2 shows the results of the Col1a1 mRNA expression level detection.

[0139] Figure 3 shows the results of ACTA2 mRNA expression level detection.

[0140] Figure 4 shows the results of the Fibronectin mRNA expression level detection.

[0141] Figure 5 provides an overview of the experiment using AK3280 to treat a rat model of bleomycin-induced idiopathic pulmonary fibrosis. Bleomycin was administered intratracheally on day 0. The compound was administered by gavage from day 8 to day 28. Lung tissue was collected on day 28 for histopathological staining.

[0142] Figure 6 shows representative images of hematoxylin-eosin stained sections of lung tissue from different groups. Unstained areas represent alveolar carcinoma.

[0143] Figure 7 shows representative images of Masson's tricolor blue stained sections of lung tissue from different groups. Unstained areas represent alveolar carcinoma.

[0144] Figure 8 compares the efficacy of AK3280 and pirfenidone (PFD) with the solvent control group. The bars, from left to right, represent the normal control group, solvent group, PFD 200 mg / kg group, AK3280 30 mg / kg group, and AK3280 100 mg / kg group. Ashcroft scores were calculated for each animal. Data are expressed as mean ± standard error; *: p < 0.05, **: p < 0.01.

[0145] Figure 9 shows the inhibitory effects of AK3280 and pirfenidone on collagen expression. The bars from left to right represent the normal group, solvent group, PFD 200 mg / kg group, AK3280 30 mg / kg group, and AK3280 100 mg / kg group, respectively. Data are expressed as mean ± standard error. *: p < 0.05, **: p < 0.01.

[0146] Figure 10 shows the overview of the Phase 2 clinical trial design for AK3280 in the first phase.

[0147] Figure 11 shows the overview of the Phase II clinical trial design for AK3280.

[0148] Figure 12 shows the change in FVC from baseline under different AK3280 doses.

[0149] Figure 13 shows the change of %pFVC from baseline under different AK3280 doses.

[0150] Figure 14 shows the changes in SGRQ score from baseline under different AK3280 doses.

[0151] Figure 15 shows the change in distance from baseline during a six-minute walk test at different AK3280 doses. Detailed Implementation

[0152] To make the technical solution and beneficial effects of the present invention more apparent and understandable, a detailed description is provided below by listing specific embodiments. The accompanying drawings are not necessarily drawn to scale, and local features may be enlarged or reduced to more clearly show the details of the local features; unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application pertains.

[0153] Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and fatal interstitial pneumonia characterized by fibrotic remodeling of lung tissue, ultimately leading to respiratory failure, with a median survival of only 2–5 years. Existing treatments, including pirfenidone and nintedanib, have been on the market for many years, but their efficacy is limited, lung function is not improved, and long-term use has significant side effects. There is an urgent clinical need for newer, more effective, and better-tolerated treatments.

[0154] This disclosure utilizes a randomized, double-blind, multicenter phase II clinical trial design to evaluate the efficacy and safety of different dose groups of AK3280 compared to a placebo control group in patients with idiopathic pulmonary fibrosis (IPF). Results showed significant efficacy after 24 weeks of treatment in the drug-treated groups, with a marked improvement in FVC in the high-dose group, particularly the 400mg group, which achieved an increase of 209.4 mL in FVC from baseline, and an adjusted %pFVC improvement of 6.4% from baseline. Compared to the placebo group, there was a significant difference in forced vital capacity (fV) improvement (p = 0.002). Other respiratory function indicators also showed varying degrees of improvement, including several clinically significant improvements. AK3280 exhibited good safety and tolerability, without the gastrointestinal discomfort or other tolerance issues associated with existing IPF drugs. Based on these findings, this invention is proposed.

[0155] One objective of this invention is to provide a method for treating idiopathic pulmonary fibrosis, comprising administering to a patient in need a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof, wherein the total daily dose of compound I is 200-1000 mg. For example, in this invention, the total daily dose of compound I is 200-900 mg, 200-800 mg, 300-1000 mg, 300-900 mg, 300-800 mg, 400-1000 mg, 400-900 mg, 400-800 mg, 500-1000 mg, 500-900 mg, 500-800 mg, 600-1000 mg, 600-900 mg, 600-800 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg.

[0156] In a preferred embodiment, the total daily dose is 200-800 mg.

[0157] In a preferred embodiment, the total daily dose is 400-800 mg.

[0158] In a preferred embodiment, the total daily dose is 600-800 mg.

[0159] The medicament or pharmaceutical composition of the present invention can be administered intravenously, orally, rectally, or sublingually. In some embodiments, the route of administration is oral. In some embodiments, the route of administration is intravenous injection. In other embodiments, the route of administration is rectal administration. In still other embodiments, the route of administration is sublingual.

[0160] In a preferred embodiment, the total daily dose is administered once, twice, or three times a day. In some embodiments, the total daily dose is administered once a day. In other embodiments, the total daily dose is administered twice a day. In still other embodiments, the total daily dose is administered three times a day.

[0161] In a preferred embodiment, the total daily dose is administered twice daily.

[0162] In a preferred embodiment, the total daily dose is 600 mg or 800 mg, administered in two equal doses. In some embodiments, the total daily dose is 600 mg, administered in two equal doses. In other embodiments, the total daily dose is 800 mg, administered in two equal doses.

[0163] In a preferred embodiment, the duration of administration of the total daily dose includes a first treatment period and / or a second treatment period. In some embodiments, the duration of administration of the total daily dose includes a first treatment period. In other embodiments, the duration of administration of the total daily dose includes both a first treatment period and a second treatment period.

[0164] In a preferred embodiment, the first treatment period is at least 12 weeks. In some embodiments, the first treatment period is 12 weeks. In a preferred embodiment, the first treatment period is at least 24 weeks. In some embodiments, the first treatment period is 24 weeks. In other preferred embodiments, the first treatment period is at least 48 weeks. In other embodiments, the first treatment period is 48 weeks. In other preferred embodiments, the first treatment period is at least 52 weeks. In other embodiments, the first treatment period is 52 weeks. In other preferred embodiments, the first treatment period is at least 104 weeks. In other embodiments, the first treatment period is 104 weeks. In other embodiments, the first treatment period is lifelong for those in need.

[0165] In any of the methods disclosed herein, there is no reduction in the daily dose administered to the patient in need during the treatment period. In any of the methods disclosed herein, there is no interruption or temporary cessation of the daily dose administered to the patient in need during the treatment period.

[0166] In a preferred embodiment, the second treatment period is at least 12 weeks. In some embodiments, the second treatment period is 12 weeks. In a preferred embodiment, the second treatment period is at least 24 weeks. In some embodiments, the second treatment period is 24 weeks. In a preferred embodiment, the second treatment period is at least 48 weeks. In other embodiments, the second treatment period is 48 weeks. In a preferred embodiment, the second treatment period is at least 52 weeks. In other embodiments, the second treatment period is 52 weeks. In a preferred embodiment, the second treatment period is at least 104 weeks. In other embodiments, the second treatment period is 104 weeks. In other embodiments, the second treatment period is lifelong for those in need.

[0167] In a preferred embodiment, the method includes administering a total daily dose selected from the group consisting of 200 mg, 400 mg, 600 mg, and 800 mg during the first treatment period. In some embodiments, the method administers a total daily dose of 200 mg of compound I during the first treatment period. In other embodiments, the method administers a total daily dose of 400 mg of compound I during the first treatment period. In still other embodiments, the method administers a total daily dose of 600 mg of compound I during the first treatment period. In yet another embodiment, the method administers a total daily dose of 800 mg of compound I during the first treatment period.

[0168] In a preferred embodiment, the method includes administering a total daily dose selected from the group consisting of 400 mg, 600 mg, and 800 mg during a second treatment period. In some embodiments, the method administers a total daily dose of 400 mg of compound I during the second treatment period. In other embodiments, the method administers a total daily dose of 600 mg of compound I during the second treatment period. In still other embodiments, the method administers a total daily dose of 800 mg of compound I during the second treatment period.

[0169] In a preferred embodiment, the person in need is an adult aged 40-80.

[0170] In a preferred embodiment, the dosage form of the pharmaceutical composition is a tablet, hard capsule, soft capsule, oral solution, drop pill, granule, or sustained-release microcapsule.

[0171] In a preferred embodiment, the pharmaceutical composition is in the form of a powder, pill, tablet, capsule, oral liquid, aerosol, or injection. In some embodiments, the pharmaceutical composition is in the form of a tablet. In some embodiments, the pharmaceutical composition is in the form of a nano-suspension tablet.

[0172] In a preferred embodiment, the treatment method reverses, prevents, delays, or slows the progression of respiratory impairment or IPF in the patient in need. In some embodiments, the treatment method reverses the progression of respiratory impairment or IPF in the patient in need. In other embodiments, the treatment method delays or slows the progression of respiratory impairment or IPF in the patient in need. Preferably, the treatment method reverses the progression of respiratory impairment in the patient in need.

[0173] In a preferred embodiment, the progression of respiratory function impairment is determined by measuring changes in forced vital capacity (FVC) and / or percentage predicted forced vital capacity (%pFVC) during the first and / or second treatment periods. In some embodiments, the progression of respiratory function impairment is determined by measuring changes in FVC during the first treatment period. In some embodiments, the progression of respiratory function impairment is determined by measuring changes in percentage predicted forced vital capacity (%pFVC) during the first treatment period. In other embodiments, the progression of respiratory function impairment is determined by measuring changes in FVC during the first and second treatment periods. In still other embodiments, the progression of respiratory function impairment is determined by measuring changes in percentage predicted forced vital capacity (%pFVC) during the first and second treatment periods. For example, the progression of respiratory function impairment is determined by measuring changes in FVC and / or percentage predicted forced vital capacity (%pFVC) during the 24-week first treatment period. In other embodiments, the progression of the respiratory function impairment is determined by measuring changes in forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) during a 24-week first treatment period and a 24-week second treatment period. In some embodiments, the treatment period for measuring changes in FVC and / or %pFVC extends from baseline to a period selected from: at least 24 weeks, at least 48 weeks, at least 52 weeks, or at least 104 weeks. In some embodiments, the treatment period for measuring changes in FVC and / or %pFVC is at least 24 weeks. In some embodiments, changes in FVC and / or %pFVC are measured from baseline to at least 24 weeks of treatment. In some embodiments, the treatment period for measuring changes in FVC and / or %pFVC is at least 48 weeks. In some embodiments, changes in FVC and / or %pFVC are measured from baseline to at least 52 weeks of treatment.

[0174] In a preferred embodiment, the method improves at least one symptom selected from the group consisting of: forced vital capacity (FVC), %pFVC, carbon monoxide diffusing capacity (DLco), St. George's Respiratory Questionnaire score (SGRQ), and 6-minute walk test distance (6MWT) compared to before treatment. In some embodiments, the method improves forced vital capacity (FVC), %pFVC, carbon monoxide diffusing capacity (DLco), St. George's Respiratory Questionnaire score (SGRQ), and 6-minute walk test distance (6MWT) compared to before treatment.

[0175] In a preferred embodiment, during a first treatment period of at least 24 weeks, the method increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) compared to before treatment. In some embodiments, during a first treatment period of at least 24 weeks, with a total daily dose of 800 mg compared to before treatment, the method increases forced vital capacity and / or percentage predicted forced vital capacity (%pFVC). In some embodiments, during a first treatment period of at least 24 weeks, with a total daily dose of 800 mg compared to before treatment, the method increases %pVC by at least 2%, preferably at least 4%, more preferably at least 6%. In some embodiments, during a first treatment period of 24 weeks, with a total daily dose of 800 mg compared to before treatment, the method increases %pVC by at least 2%, preferably at least 4%, more preferably at least 6%. For example, during the first treatment period of 24 weeks, with a total daily dose of 800 mg compared to before treatment, the method increases forced vital capacity by 1%-7%, 2%-6.5%, 3%-7%, 4%-6.5%, 5%-7%, 5%-6.5%, 3%, 4%, 5%, 6%, 6.4%, 6.5%, or 7%. Preferably, during the first treatment period of 24 weeks, with a total daily dose of 800 mg compared to before treatment, the method increases %pFVC by 6.4%. In some embodiments, during the first treatment period of at least 24 weeks, with a total daily dose of 600 mg compared to before treatment, the method increases forced vital capacity and / or %pFVC. In some embodiments, during the first treatment period of 24 weeks, with a total daily dose of 600 mg compared to before treatment, the method increases %pFVC by at least 1%, preferably at least 2%, and more preferably at least 3%. For example, during the first 24-week treatment period, compared to the pre-treatment total daily dose of 600 mg, the method increases %pFVC by 1%-4%, 1.5%-4%, 2%-4%, 2.5%-4%, 3%-4%, 1%-3.5%, 1.5-3.5%, 2%-3.5%, 2.5%-3.5%, 3%-3.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.3%, 3.5%, and 4%. Preferably, during the first 24-week treatment period, compared to the pre-treatment total daily dose of 600 mg, the method increases %pFVC by 3.3%.

[0176] In a preferred embodiment, the method reduces the St. George Respiratory Questionnaire (SGRQ) score compared to pre-treatment levels during a first treatment period of at least 12 weeks. In some embodiments, the method reduces the SGRQ score during a 12-week first treatment period compared to pre-treatment levels. In some embodiments, the method reduces the SGRQ score during a 24-week first treatment period compared to pre-treatment levels. In some embodiments, the method reduces the SGRQ score during a 48-week first treatment period compared to pre-treatment levels.

[0177] In a preferred embodiment, during a first treatment period of at least 12 weeks, with a total daily dose of 800 mg compared to before treatment, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score by at least 2 points, preferably at least 3 points, and more preferably at least 4 points. In some embodiments, during a first treatment period of 12 weeks, with a total daily dose of 800 mg compared to before treatment, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score by at least 2 points, preferably at least 3 points, and more preferably at least 4 points. For example, during the first treatment period of at least 12 weeks, compared to before treatment with a total daily dose of 800 mg, the method resulted in a reduction in St. George's Respiratory Questionnaire (SGRQ) scores of 2-5, 2.5-5, 3-5, 3.5-5, 4-5, 4.5-5, 2-4.5, 2.5-4.5, 3-4.5, 3.5-4.5, 4-4.5, 2, 2.5, 3, 3.5, 4, 4.1, 4.5, and 5. In a preferred embodiment, during the first treatment period of 12 weeks, compared to before treatment with a total daily dose of 800 mg, the method resulted in a reduction in St. George's Respiratory Questionnaire (SGRQ) score of 4.1.

[0178] In a preferred embodiment, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score compared to pre-treatment levels during a first treatment period of at least 24 weeks. In some embodiments, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score compared to pre-treatment levels during a first treatment period of 24 weeks. In some embodiments, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score compared to pre-treatment levels during a first treatment period of 48 weeks.

[0179] In a preferred embodiment, during a first treatment period of at least 24 weeks, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score by at least 4 points, preferably at least 5 points, and more preferably at least 6 points compared to before treatment, when a total daily dose of 800 mg is administered. In some embodiments, during a first treatment period of 24 weeks, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score by at least 4 points, preferably at least 5 points, and more preferably at least 6 points compared to before treatment, when a total daily dose of 800 mg is administered. For example, during a first treatment period of 24 weeks, the method reduces the St. George's Respiratory Questionnaire (SGRQ) score by 4-8 points, 5-8 points, 6-8 points, 4-7 points, 5-7 points, 6-7 points, 4 points, 4.5 points, 5 points, 5.5 points, 6 points, 6.2 points, 6.5 points, and 7 points compared to before treatment, when a total daily dose of 800 mg is administered. In a preferred embodiment, during the first treatment period of 24 weeks, the method reduced the St. George Respiratory Questionnaire (SGRQ) score by 6.2 points compared to before treatment, when a total daily dose of 800 mg was administered.

[0180] In a preferred embodiment, during a first treatment period of at least 24 weeks, the method reduces the rate of 6MWT worsening compared to before treatment; preferably, the method reduces the rate of 6MWT decline by more than 50 mg / L. In some embodiments, during a first treatment period of 24 weeks, the method reduces the rate of 6MWT worsening compared to before treatment. In other embodiments, during a first treatment period of 48 weeks, the method reduces the rate of 6MWT worsening compared to before treatment.

[0181] In a preferred embodiment, during a first treatment period of at least 24 weeks, a total daily dose of 600 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 20%, preferably less than 18%, and more preferably less than 17% compared to pre-treatment levels. In some embodiments, the reduction is less than 20%, preferably less than 18%, and more preferably less than 17%. For example, during a first treatment period of 24 weeks, a total daily dose of 800 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 15%-20%, 16%-19%, 16%-18%, and 16-17% compared to pre-treatment levels. In a preferred embodiment, during a first treatment period of 24 weeks, a total daily dose of 800 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 16.7% compared to pre-treatment levels.

[0182] In a preferred embodiment, during a first treatment period of at least 24 weeks, a total daily dose of 800 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 15%, preferably less than 12%, more preferably less than 10%, compared to pre-treatment levels. In some embodiments, during a first treatment period of 24 weeks, a total daily dose of 800 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 15%, preferably less than 12%, more preferably less than 10%, compared to pre-treatment levels. For example, during a first treatment period of 24 weeks, a total daily dose of 800 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 5% by less than 5% to 5-15%, 6-12%, 7-10%, 7%-9%, or 8%-9%, compared to pre-treatment levels. In a preferred embodiment, during a first treatment period of 24 weeks, a total daily dose of 800 mg is administered, and the method reduces the percentage of 6MWT reductions exceeding 50 m by less than 8.7%, compared to pre-treatment levels.

[0183] In a preferred embodiment, the method exhibits a reduction in at least one adverse event selected from the group consisting of: rash, photosensitivity, nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, loss of appetite, constipation, headache, dizziness, drowsiness, fatigue, drug intolerance, elevated AST, ALT, GGT, and hepatotoxicity. In some embodiments, the method exhibits a reduction in at least one gastrointestinal-related adverse event selected from the group consisting of: nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, decreased appetite, and constipation. In some embodiments, the method exhibits a reduction in at least one neurological-related adverse event selected from the group consisting of: headache, dizziness, and drowsiness. In some embodiments, the method exhibits a reduction in at least one liver function-related adverse event selected from the group consisting of: elevated AST, ALT, GGT, and hepatotoxicity. In some embodiments, the method exhibits a reduction in at least one skin-related adverse event selected from the group consisting of: rash and photosensitivity. In a preferred embodiment, the method exhibits a reduction in elevated GGT. In a preferred embodiment, the method exhibits a reduction in gastrointestinal adverse events (including diarrhea, indigestion, nausea, bloating, flatulence, etc.). In a preferred embodiment, the method exhibits reduced diarrhea.

[0184] In a preferred embodiment, the patient in need meets the conditions of %FVC≥50% and ≤90% and %DLco≥30% and ≤90% before starting treatment.

[0185] In a preferred embodiment, the patient in need has not received prior treatment for IPF. In some embodiments, the patient in need has not previously received nintedanib and / or pirfenidone treatment. In some embodiments, the patient in need has not previously received nintedanib and pirfenidone treatment.

[0186] In a preferred embodiment, the patient in need has received prior treatment for IPF. In some embodiments, the patient in need has previously received treatment with nintedanib and / or pirfenidone. In some embodiments, the patient in need has previously received treatment with nintedanib and pirfenidone.

[0187] definition

[0188] The term "adverse event" refers to any event, side effect, or other adverse medical event that occurs in humans in conjunction with the use of a pharmaceutical product, whether or not it is considered causally related to the treatment. Therefore, an AE can be any adverse and unexpected sign (which may include clinically significant abnormal laboratory findings), symptom, or illness that is temporarily associated with the use of the pharmaceutical product, whether or not it is considered related to the pharmaceutical product. Events that meet the definition of an AE include: exacerbation of a chronic or intermittent pre-existing condition, including an increase in the frequency and / or intensity of that condition; a new condition that occurs within the reporting period after administration of the study drug, even if it may have existed before the start of the study; signs, symptoms, or clinical sequelae of suspected interaction; signs, symptoms, or clinical sequelae of suspected overdose of the study drug or accompanying drug (overdose itself will be reported as an AE / SAE). AEs may be causally related to the treatment, may be related, or may not be related. The severity of an AE can be classified into one of the following: Mild (Level 1): A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event generally does not interfere with daily living activities; Moderate (Level 2): ​​A type of AE that is usually relieved by additional specific therapeutic intervention. The event interferes with daily living activities and causes discomfort, but does not pose a significant or permanent risk of harm to the study participant; Severe (Level 3): A type of AE that interrupts daily living activities or significantly affects clinical status, or may require intensive therapeutic intervention; Life-threatening (Level 4): A type of AE that puts the participant at immediate risk of death; Death (Level 5): An event that results in death.

[0189] As used in this article, the terms “clinically effective dose” and “clinically proven effective dose” refer to the effective dose of an API as demonstrated by clinical trials, such as those conducted by the FDA or CDE.

[0190] As used herein, the term "therapeutic effective amount" refers to an amount of compound sufficient to cure, improve, slow the progression of, prevent or reduce the likelihood of a known disease or symptom, or to exhibit a detectable therapeutic, preventive, or inhibitory effect. For example, such effects can be detected by experiments as described in the following example invention. The precise effective amount for a subject depends on the subject's weight, health status, the nature and severity of the symptom, and the choice of the therapeutic agent or combination of therapeutic agents for administration. The therapeutic and preventive effective amount for a given situation can be determined through routine experiments within the skill and judgment of a clinician.

[0191] The term "fibrosis" refers to the deposition of extracellular matrix components, excessive fibrous connective tissue, or scar formation within an organ or tissue.

[0192] The term "idiopathic pulmonary fibrosis (IPF)" refers to a type of lung disease that leads to lung scarring (pulmonary fibrosis) and whose origin may be unknown.

[0193] The terms “recipient,” “subject,” “application subject,” and “subject” refer to mammals that are in need or are subjects, including human patients or subjects. In some implementations, patients are human subjects.

[0194] Terms such as “treating” or “treatment” or “to treat” refer to therapeutic measures that: reverse, avoid, delay and / or slow the occurrence of one or more symptoms of a pathological condition or symptom; reverse, avoid, delay and / or slow the progression of one or more symptoms; reverse, prevent, cure, improve or alleviate one or more symptoms; and / or avoid the occurrence of a pathological condition or symptom; reverse, prevent, cure, improve a pathological condition or symptom; reverse or slow the progression of a pathological condition or symptom; and / or stop the progression of a pathological condition or symptom.

[0195] In some implementations, treatment may be administered after one or more symptoms have developed. Therefore, those requiring treatment include those already suffering from a condition (e.g., IPF). In some implementations, treatment may be administered after one or more symptoms have developed. In some implementations, a subject is successfully “treated” against a disease or condition if the patient exhibits, for example, a reversal, partial or temporary relief or elimination of one or more symptoms associated with the disease or condition (e.g., IPF), or if the patient exhibits, for example, a partial or temporary delay in the progression of one or more symptoms associated with the disease or condition (e.g., IPF), and / or if the patient exhibits, for example, a reversal in the progression of one or more symptoms associated with the disease or condition (e.g., IPF), including, for example, impaired respiratory function and pulmonary fibrosis, and other known symptoms of IPF, or a partial or temporary reduction (decrease, decrease) in the rate of progression.

[0196] Interstitial lung disease

[0197] Interstitial lung disease (ILD) encompasses a large and diverse group of over 200 lung and respiratory diseases, characterized by inflammation and fibrosis of the interstitium, and the tissue and spaces between the lung sacs (see, for example, du Bois, Nat. Rev. Drug Discov. 2010, 9, 129-140). ILD involves the alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular tissue, and perilymphatic tissue. ILD can occur when lung injury triggers an abnormal healing response. Normally, the body produces an adequate amount of tissue to repair the damage. However, in ILD, the repair process goes awry, and the tissue surrounding the sacs (alveoli) scars and thickens. This makes it more difficult for oxygen to enter the bloodstream. Interstitial lung disease (ILD) is generally divided into two main categories: non-progressive fibrotic ILD (such as some types of hypersensitivity pneumonitis, non-fibrotic NSIP, etc.) and "progressive fibrotic" ILD (PF-ILD).

[0198] Progressive fibrotic interstitial lung disease (PF-ILD)

[0199] International expert consensus guidelines consider PF-ILD to be an old term (see journal: Rajan SK, Cottin V, Dhar R, et al., 2023. Progressive pulmonary fibrosis: an expert group consensus statement[J]. The European Respiratory Journal, 61(3):2103-187.), which can be replaced by the new term Progressive Pulmonary Fibrosis (PPF). However, Chinese experts, after reviewing the history of terminology evolution, believe (see journal: Xu Wenshuai, Mou Xiangdong, 2025. Is Progressive Fibrotic Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Plus Progressive Pulmonary Fibrosis[J]. Chinese Journal of Tuberculosis and Respiratory Disease (06): June 12, 2025.) that PPF cannot replace PF-ILD, and PF-ILD should include IPF and PPF. PPF refers to the general term for progressive fibrotic interstitial lung diseases other than IPF, which is a clinical phenotype rather than a specific pathological type. PPF can occur in various underlying ILDs, such as CTD-ILD, HP, and NSIP. Its disease progression is similar to that of IPF, and its prognosis is poor. PPF is defined as disease progression within 24 months after appropriate management of the underlying disease (i.e., after standard treatment). Progression criteria include: a decrease in FVC ≥5-10% (relative value); and / or increased fibrosis on HRCT (new or worsening); and / or worsening of respiratory symptoms (increased cough, dyspnea).

[0200] As demonstrated in CN111278442B, ILD, PPF, and IPF share a common pathogenesis of fibrosis, and therapeutic agents targeting the basic process of progressive pulmonary fibrosis in IPF will induce a similar therapeutic effect in PPF.

[0201] AK3280

[0202] The method disclosed herein includes the administration of AK3280 to treat IPF. AK3280, formerly known as GDC-3280 and AKEX0011, has the chemical name (1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one), and has been disclosed in patent WO2014055548A1. Preclinical studies have shown that AK3280 has a broad-spectrum anti-fibrotic mechanism and has the potential to treat IPF. AK3280 has the following structure:

[0203] The “AK3280” mentioned in this article further includes any hydrate, salt, solvate, crystalline polymorph, amorphous form, etc. of (1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-5-(4-(trifluoromethyl)phenyl)-1,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one).

[0204] In this disclosure, AK3280 is manufactured using conventional raw materials that are commercially available. It can also be synthesized using known and publicly disclosed methods. AK3280, its preparation, crystal structure, and preparation process are described in international publications WO2019152863A1 and WO2014055548A1. The contents of each of these documents are incorporated herein by reference in their entirety.

[0205] As used herein, “and / or” means “any one or both” of the elements so combined, that is, elements that exist together in some cases and separately in others. Therefore, as a non-limiting example, when used in conjunction with open-ended language such as “comprising,” “A and / or B” may in some embodiments refer only to A (optionally including elements other than B); in other embodiments, only to B (optionally including elements other than A); in still other embodiments, to both A and B (optionally including other elements); and so on.

[0206] As used herein, when numerical values ​​are listed individually or as part of a range of values, it should be understood that the values ​​may vary above and below the values ​​with reasonable variance for the values, as would be recognized by those skilled in the art.

[0207] As used herein, the term “approximately” or “about” applied to one or more values ​​of interest means a value similar to the reference value. In some embodiments, the term refers to a range of values ​​falling within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the reference value, unless otherwise stated or apparent from the context.

[0208] This article discloses a method for treating idiopathic pulmonary fibrosis, comprising administering to patients in need a total daily dose of 200-1000 mg of a pharmaceutical composition comprising compound I or a pharmaceutically acceptable salt thereof. Compared with existing approved drugs, this method is expected to provide significantly increased efficacy, tolerability, and patient compliance in these subjects.

[0209] The phase 3 clinical trial data of pirfenidone for the treatment of IPF has been published in WO2023133476A1, and the contents of paragraphs 161 to 165 are incorporated herein by reference.

[0210] Example 1: Preparation of Compound I (AK3280)

[0211] The free base crystalline compound (type A) of AK3280 was prepared according to steps 1-7 of Example 13 in WO2019152863A1, and its XRD pattern is disclosed in Figure 1 of WO2019152863A1. The disclosure of WO2019152863A1 is incorporated herein by reference in its entirety.

[0212] Example 2: Fibroblast-Myofibroblast Transformation (FMT) Experiment

[0213] Interstitial lung diseases (ILDs) encompass over 160 types, including progressive and non-progressive pulmonary fibrosis. These diseases share the common characteristic of varying degrees of inflammation and pulmonary fibrosis. The pathological mechanism involves damage to alveolar epithelial cells, which triggers immune dysregulation, fibroblast proliferation, myofibroblast differentiation, and excessive extracellular matrix (ECM) deposition, ultimately forming a self-amplifying vicious cycle of fibrosis. Mechanical stress and ECM components further exacerbate the fibrotic process. Fibroblasts are the core cells in the development of pulmonary fibrosis. Under fibrotic pathological conditions, fibroblasts transform into myofibroblasts, secreting large amounts of ECM, altering the biomechanical properties of lung tissue, and dominating the process of pulmonary fibrosis remodeling. M. et al. Eur J Med Res 30, 1232 (2025). Therefore, drugs that inhibit the transformation of fibroblasts into myofibroblasts can theoretically improve pulmonary fibrosis in patients with ILD, PPF, and IPF, and treat the disease.

[0214] 2.1 Experimental Procedure:

[0215] Day 1: Cell Seeding. ① Prepare an NHLF cell suspension with a concentration of 100,000 cells / ml; ② Using a pipette, aspirate the cell suspension containing culture medium and seed 100 μL of cells into each well of a 96-well plate. Cover the plate and let it stand at room temperature on the lab bench for 30 minutes to allow the cells to settle evenly to the bottom of the wells; ③ Incubate overnight at 37°C with 5% CO2.

[0216] 2. Day 2: Serum starvation. ① Discard the serum-containing culture medium; ② Wash once with 100 μL of pre-warmed serum-free culture medium; ③ Add another 100 μL of serum-free culture medium; ④ Incubate overnight at 37°C with 5% CO2.

[0217] 3. Day 3: Cytokine stimulation and compound treatment. ① Add 200 μM AK3280 to the corresponding cell culture medium; ② Incubate the cells in a 37°C, 5% CO2 incubator for 1 hour; ③ Use growth factor-free FBM medium, add 20 μl of 6× TGF-β1 (final concentration 5 ng / ml) and the test compound at the working concentration; ④ Incubate the cells in a 37°C, 5% CO2 incubator for another 48 hours.

[0218] 4. Day 5: RT-qPCR was used to detect the mRNA levels of Col1A1, ACTA2, and FN1. ① Follow the Cells-to-CT procedure. TM The instructions describe how to extract RNA from lysed cells and convert it into cDNA. The qPCR reaction conditions are as follows:

[0219] Take an enzyme-free centrifuge tube at room temperature and prepare the PCR reaction mixture according to the system in Table 1 below.

[0220] Table 1 PCR reaction mixture system

[0221] Set up the real-time fluorescence quantitative PCR instrument according to the procedure in Table 2, and put the sample in for testing.

[0222] Table 2. Real-time Quantitative PCR Program

[0223] 5. Calculation process

[0224] ①ΔCT=CT 目的基因 -CT 内参基因 ;

[0225] ② Calculate the average value of ΔCT in the control group;

[0226] ③ΔΔCT=ΔCT 待测样本 -ΔCT 对照组平均值 ;

[0227] ④ Relative expression level = 2 -ΔΔCt .

[0228] 2.2 Experimental Results

[0229] α-SMA, COL1A1, and Fibronectin are classic biomarkers of FMT, among which ACTA2 is the gene encoding α-SMA.

[0230] Figures 2-4 show that the TGF-β1 group significantly upregulated the mRNA levels of ACTA2, Col1a1, and Fibronectin in human primary lung fibroblasts (NHLF), indicating that TGF-β1 can induce the fibroblast-myofibroblast transformation process. The AK3280 group showed that AK3280 significantly inhibited TGF-β1-induced FMT, significantly reducing the mRNA expression levels of Col1a1, ACTA2, and Fibronectin. Therefore, AK3280 has the potential to treat the fibrotic process of interstitial lung disease.

[0231] Example 3. Bleomycin-induced rat pulmonary fibrosis animal model

[0232] Interstitial lung disease (ILD) encompasses a large class of chronic lung diseases, all characterized by varying degrees of lung inflammation and fibrosis. Since no natural model of idiopathic pulmonary fibrosis (IPF) exists, there is a pressing need to develop animal models that can replicate the core characteristics of the disease. To this end, researchers have developed various animal models to explore the key mechanisms of IPF pathogenesis and to screen for potential therapeutic targets for IPF. While no single animal model can fully replicate all the pathological features of the disease in humans, several models can simulate some typical characteristics of IPF and other fibrotic interstitial lung diseases.

[0233] Bleomycin model is one of the earliest developed and most widely used classic models, and it is also the most thoroughly studied and widely used animal model. This model can simulate multiple pathological features of idiopathic pulmonary fibrosis and other fibrotic interstitial lung diseases, with good experimental reproducibility and simple modeling operation (Reference: Liu, T., De Los Santos, FG, Phan, SH (2017). The Bleomycin Model of Pulmonary Fibrosis. In: Rittié, L. (eds) Fibrosis. Methods in Molecular Biology, vol 1627. Humana Press, New York, NY. https: / / doi.org / 10.1007 / 978-1-4939-7113-8_2). Experimental results showed that AK3280 improved pulmonary fibrosis and collagen deposition, suggesting that AK3280 may inhibit the progression of fibrosis in ILD, IPF, and PPF. The specific experimental design and results are as follows:

[0234] Bleomycin-induced rodent pulmonary fibrosis models are the most widely used animal models for studying the potential of compounds as novel therapies for idiopathic pulmonary fibrosis (IPF) and can be used to evaluate the efficacy of compounds in treating IPF.

[0235] Fifty-five male Wistar rats (purchased from Charles River Laboratories, weighing 251 g to 275 g) were divided into five groups: a normal control group (n=8) without bleomycin induction, a solvent control group (n=12), a pirfenidone group (PFD 200 mg / kg twice daily) (n=12), an AK3280 group (30 mg / kg twice daily) (n=12), and an AK3280 group (100 mg / kg twice daily) (n=11). AK3280 or pirfenidone was prepared as an oral formulation dissolved in 0.5% methylcellulose (solvent) for administration. Rats in the solvent control group, pirfenidone group, and AK3280 group received a single dose of bleomycin sulfate (1.25 mg / kg) intratracheally on day 0, and received the corresponding compound treatment (pirfenidone 200 mg / kg or compound I (30 or 100 mg / kg, twice daily) from day 8 to day 28. On day 28, all animals were anesthetized with 100% oxygen containing 5.0% isoflurane, intubated via endotracheal intubation, and placed on a positive pressure ventilator. Animals were maintained at the surgical anesthesia level (100% oxygen containing 2.0% isoflurane) and continuously ventilated. Lung tissue was collected for histopathological staining (see Figure 5). The left lung lobe was collected and immersed in 10% neutral buffered formalin for 48 hours, then transferred to 70% ethanol for further histological processing and analysis. Fixed tissue specimens were embedded in paraffin, cut into (4 μm) sections of different anatomical regions, mounted, and stained with hematoxylin and eosin (H&E) or Masson's tricolor blue (MTB). Three tissue sections from different anatomical sites were taken from each animal, representing the apex, middle, and base of the lung, for a more comprehensive sampling and characterization of lung injury. Lung sections were graded using the Ashcroft score by a veterinary pathologist. Each slide was examined at 20x magnification, and the scores from five representative fields were averaged to obtain the lung lobe score. The average of the three lung lobe scores for each animal was used to obtain the individual score for that animal. The average of the individual scores for each experimental group was calculated to determine the mean for each group. All statistical analyses were performed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, California, USA). For the bleomycin-induced idiopathic pulmonary fibrosis (IPF) model study, unpaired Student's t-tests were used to analyze differences. For other studies, differences between two or more groups were analyzed using one-way ANOVA, followed by unpaired Dunnett's multiple comparison test. A p-value less than 0.05 was considered statistically significant.

[0236] Figures 6 and 7 show the histopathological changes in lung structures assessed based on Ashcroft scores and collagen volume fraction (CVF) after 21 days of treatment with the designated drugs. As shown in Figure 6, rats in the solvent group, which received bleomycin challenge and solvent treatment, exhibited moderate to severe lung lesions, characterized by bullous formation, edema, and / or eosinophilic inflammation, as well as fibrosis, indicating a successful establishment of a bleomycin-induced idiopathic pulmonary fibrosis model. Compounds AK3280 (30 and 100 mg / kg) and pirfenidone (200 mg / kg) effectively reduced this structural damage in the lungs with fewer fibrotic lesions. As shown in Figure 8, compared to the solvent group, the Ashcroft scores of the 30 and 100 mg / kg AK3280 groups (BID) were reduced by 12.9% (p<0.05) and 12.1% (p<0.05), respectively. The control compound pirfenidone group reduced the Ashcroft score by 5%.

[0237] The degree of pulmonary fibrosis was measured by quantifying the collagen volume fraction (CVF) in all groups. As shown in Figure 9, compared with the solvent group, treatment with AK3280 at 30 and 100 mg / kg (BID) reduced collagen volume fraction by 33.6% (p<0.01) and 32.6% (p<0.01), respectively. Treatment with pirfenidone reduced collagen volume fraction by 16.4%, but this was not significantly different from the excipient group (p=0.11). Therefore, AK3280 has a better anti-fibrotic effect than the commercially available drug pirfenidone.

[0238] Example 4: Preparation of AK3280 tablets and placebo tablets

[0239] The composition of the AK3280 tablets and placebo tablets used in this disclosure is shown in Table 3 below:

[0240] Table 3 Composition of AK3280 tablets and placebo tablets

[0241] The fabrication process of the AK3280 sheet used in this disclosure has been disclosed in Example 14 of WO2019152863A1, the contents of which are incorporated herein by reference in their entirety.

[0242] The preparation method for placebo tablets is the same as that for AK3280 tablets.

[0243] Example 5: Phase II Clinical Trial

[0244] This is a randomized, double-blind, multicenter phase II clinical trial to evaluate the efficacy and safety of two different dose groups of AK3280 compared to placebo in patients with idiopathic pulmonary fibrosis (IPF) (Registration No.: CTR20221183). The aim of this trial is to evaluate the efficacy of AK3280 in IPF patients relative to placebo by measuring the percentage of forced vital capacity (%FVC), as well as other clinical efficacy of AK3280 compared to placebo in IPF patients, assess the safety and tolerability of AK3280, and evaluate the pharmacokinetic characteristics of AK3280 and its metabolites in IPF patients. The primary endpoint of this clinical study is the frequency and severity of adverse events and serious adverse events during the 12-week treatment period.

[0245] 5.1 Subject Screening

[0246] Subjects meeting the following criteria were eligible for enrollment: age between 40 years (minimum age) and 80 years (maximum age); patients with a confirmed diagnosis of IPF based on HRCT and pathology (if applicable) combined with clinical manifestations, with the diagnosis of IPF requiring reconfirmation during screening assessment according to the latest 2022 guidelines of the American Thoracic Society / European Respiratory Society / Japanese Respiratory Society / Latin American Thoracic Society (ATS / ERS / JRS / ALAT); patients who had previously received pirfenidone or nintedanib but had discontinued the medication for more than 4 weeks prior to randomization, or patients who had not previously received pirfenidone or nintedanib; at screening, %FVC between 50% and 90% (inclusive), and %DLco (hemoglobin-corrected) between 30% and 90% (inclusive); relatively stable baseline lung function, with a relative difference of <10% between the FVC values ​​on the screening day and the day before administration; and a 6MWT distance ≥100 meters without support.

[0247] Exclusion criteria were: interstitial pneumonia of other known causes; patients scheduled for lung transplantation within 6 months of screening; patients with clinically significant lung diseases other than IPF (such as asthma, COPD, etc.); and forced expiratory volume in one second (FEV1) / FVC ratio <0 at the time of screening after using a bronchodilator.7; Positive bronchodilator test, characterized by an increase in FEV1 ≥12% and an absolute increase in FEV1 ≥200 mL after bronchodilator administration; resting peripheral capillary oxygen saturation (SpO2) <88%; suffering from any clinically diagnosed connective tissue disease, including but not limited to scleroderma, polymyositis / dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis; New York Heart Association (NYHA) functional class III-IV; renal insufficiency or a history of kidney injury; or creatinine clearance <60 mL / min, calculated using the Cockcroft-Gault formula; or end-stage renal disease requiring dialysis; or uncontrolled blood glucose at screening time. Patients with HbA1c > 10% or higher; patients hospitalized within 4 weeks prior to or during the screening period due to acute exacerbation of IPF; patients currently diagnosed with or assessed as likely to have malignancy (excluding localized basal cell carcinoma of the skin or cervical cancer in situ); patients hospitalized for ≥ 24 hours within 4 weeks prior to or during the screening period due to local or systemic infection, or those who used antibiotics within 4 weeks prior to or during the screening period; patients in the acute phase of severe pulmonary infection; patients with active pulmonary tuberculosis requiring treatment within 12 months prior to the screening period; patients with known immunodeficiency, including but not limited to HIV infection; patients who have received regular corticosteroid treatment within 4 weeks prior to or during the screening period, or patients who require this treatment during the study period. Patients with acute or chronic hepatitis or known cirrhosis and abnormal liver function; patients who have received maintenance therapy with immunosuppressive or immunomodulatory drugs, cytotoxic drugs (such as colchicine), pirfenidone, tyrosine kinase inhibitors (such as nintedanib), or pulmonary hypertension drugs within 4 weeks or 5 half-lives (whichever is longer) prior to randomization; patients using P-glycoprotein inhibitors or substrates of transporters OAT1, OAT3, OCT2, MATE2-K, or MATE1, with the time interval between the first treatment with the study drug being less than 5 half-lives of the aforementioned drugs; patients with a history of alcohol consumption, drug or chemical abuse, which the investigators believe may impair or affect their full participation in this study; patients who, for various reasons, are unable to participate... Patients who are on long-term oral medications, such as those with esophageal stricture or difficulty swallowing medications; patients who have not abstained from smoking within the 3 months prior to screening; patients whose 12-lead ECG results at screening show a QTcF interval >450 msec for men and >460 msec for women; patients with a family or personal history of QT prolongation syndrome; patients with any disease other than IPF with a life expectancy of <12 months; patients requiring long-term medical care; patients with limited self-care ability; or patients whom the investigator believes may affect their participation in completing this clinical study, completing study-related examinations, or affecting safety or efficacy assessments (e.g., pregnant or lactating women, women of childbearing age who are unwilling to use highly effective contraceptives, and men, etc.).

[0248] 5.2 Experimental Design and Supervision

[0249] The study design includes a main study and an extension study. The main study includes a 4-week screening period, a 24-week medication observation period, and a 4-week safety follow-up period. The extension study includes a 24-week medication observation period and a 4-week safety follow-up period.

[0250] The entire study was conducted in two phases. In the first phase, approximately 54 IPF patients who completed screening and assessment and met the enrollment criteria were randomly assigned in a 1:1:1 ratio to three treatment groups: AK3280 100mg BID, AK3280 200mg BID, and placebo BID. Randomization was stratified based on whether patients had previously received pirfenidone or nintedanib. The safety of the drugs was assessed after approximately 30 subjects completed 12 weeks of treatment. If both dose groups of AK3280 showed satisfactory safety, patients could proceed to the second phase (high-dose group + placebo group). The second phase was expected to enroll 51 IPF patients, who were randomly assigned in a 3:3:1 ratio to the AK3280 300mg BID, AK3280 400mg BID, and placebo BID groups. The trial design for both phases is shown in Figures 10 and 11.

[0251] 5.3 Randomization and Blinding

[0252] This was a randomized, double-blind, placebo-controlled trial. AK3280 tablets were identical in appearance to the placebo, and all participants remained blinded. Participants were numbered according to their screening order and randomly assigned on Day 1 to either the AK3280 100mg, 200mg, or placebo group (1:1:1), stratified by prior use of pirfenidone / nintedanib. If the DMC recommended progression to Phase II, new participants were randomly assigned to the 300mg, 400mg, or placebo group in a 3:3:1 ratio; otherwise, they continued with the Phase I dose group in a 3:3:1 ratio.

[0253] Interim analyses were performed by an independent statistical team, and only that team and the DMC unblinded the data. Physicians involved in pulmonary function and 6MWT assessments were not involved in adverse event and symptom evaluation and remained blinded. Randomization codes were generated by an independent statistician and kept confidential; randomization numbers for withdrawn researchers were not reused.

[0254] The experimental grouping and dosing regimen are as follows:

[0255] 100mg dose group: 100mg tablets (AK3280 tablets or placebo), orally, twice daily, one AK3280 100mg tablet and one placebo tablet each time.

[0256] 200mg dose group: 100mg tablets (AK3280 tablets or placebo), orally, twice daily, two AK3280 100mg tablets each time.

[0257] 300mg dose group: 100mg tablets (AK3280 tablets or placebo), orally, twice daily, with each dose consisting of 3 AK3280 100mg tablets and 1 placebo tablet.

[0258] 400mg dose group: 100mg tablets (AK3280 tablets or placebo), orally, twice daily, 4 tablets of AK3280 100mg each time.

[0259] All treatment groups or placebo groups were given the medication twice a day, Q12h (i.e., once every 12 hours, with a time window of ±1h), and it was taken within 30 minutes after a meal.

[0260] 5.4 Endpoint Indicators and Evaluation

[0261] Primary study endpoint

[0262] The frequency and severity of adverse events and serious adverse events during the 12-week treatment period.

[0263] Secondary research endpoints

[0264] (1) Other safety endpoints

[0265] 1. Frequency and severity of TEAE and SAE during the 24-week and 48-week treatment periods.

[0266] 2. The proportion of subjects in the AK3280 treatment group and the placebo control group who discontinued, stopped, or withdrew from the study due to adverse events.

[0267] 3. Other safety assessment indicators, including vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory tests (complete blood count, blood biochemistry, urinalysis), etc.

[0268] (2) Efficacy endpoint indicators

[0269] 1. After 12 and 24 weeks of continuous treatment, the absolute decrease in %FVC from baseline was observed in the AK3280 treatment group compared to the placebo control group.

[0270] 2. Progression-free survival

[0271] 3. The absolute decrease in hemoglobin-corrected %DLco value from baseline within 12, 24, and 48 weeks of medication, and the proportion of subjects whose absolute %DLco value decreased by ≥15% from baseline within 12, 24, and 48 weeks of medication.

[0272] 4. The decrease in FVC from baseline within 12, 24, and 48 weeks of medication.

[0273] 5. The proportion of subjects whose FVC decreased by ≥10%, ≥15%, and ≥20% within 12, 24, and 48 weeks of medication, respectively.

[0274] 6. The time until the FVC decreases by 10% relative to the baseline

[0275] 7. Changes in 6MWT distance from baseline during 12, 24, and 48 weeks of medication.

[0276] 8. During the study period, the time from randomization to the first acute exacerbation of IPF.

[0277] 9. Incidence of acute exacerbations of IPF during the study period

[0278] 10. IPF-related mortality rate

[0279] 11. All-cause mortality rate of IPF

[0280] 12. Changes in St. George's Respiratory Questionnaire (SGRQ) scores relative to baseline during 12, 24, and 48 weeks of medication; proportion of subjects with SGRQ scores ≥4 points from baseline during 12, 24, and 48 weeks of medication.

[0281] (3) Pharmacokinetic evaluation indicators

[0282] Pharmacokinetic (PK) parameters of AK3280 and AK3280 M2 on days 1 and 7 of administration, including but not limited to:

[0283] 1. Peak plasma drug concentration (Cmax)

[0284] 2. Peak time (Tmax)

[0285] 3. Area under the plasma drug concentration-time curve from 0 hours to 12 hours (AUC0-12h)

[0286] 4. Extrapolate from 0 hours to infinity. Area under the plasma drug concentration-time curve (AUC0-∞)

[0287] 5. Oral clearance (CL / F)

[0288] 6. Oral distribution volume (Vd / F)

[0289] 7. Terminal half-life (t1 / 2)

[0290] 8. Accumulation coefficient

[0291] 5.5 Data Statistics and Analysis

[0292] This study aimed to evaluate the safety, tolerability, and efficacy of different doses of AK3280 in treating IPF. The primary analysis was performed after all subjects completed 24 weeks of treatment, and the final analysis was conducted after the extension study and 4-week follow-up.

[0293] Commonly used statistical methods:

[0294] For continuous variables, descriptive statistics (such as mean, standard deviation, median, etc.) are used, and for categorical variables, frequencies and percentages are summarized. Analyze using SAS 9.4 or later.

[0295] Safety analysis: Based on the safety set, adverse events, laboratory tests, vital signs, physical examinations, and electrocardiograms are assessed. Quantitative indicators are presented in statistical summaries, and qualitative indicators are summarized in cross-tabulations. Adverse events are coded according to MedDRA v25.0 and classified according to CTCAE 5.0, and a detailed list is provided.

[0296] Efficacy analysis: based on the full analysis set (FAS).

[0297] • Continuous variables (such as FVC, DLco, SGRQ, 6MWT): The MMRM model is used to assess the changes from the baseline at each time point, and the least squares mean, difference, confidence interval and p-value are reported.

[0298] • For binary variables (such as the percentage decrease in FVC): use the CMH test to estimate the difference in rates between groups and its confidence interval.

[0299] • Time-related event variables (e.g., time when FVC decreases by ≥10%): Kaplan-Meier method, survival curves, Log-rank test, and Cox model analysis were used.

[0300] Evaluation of research indicators

[0301] Before screening begins, participants must sign an informed consent form. Assessment of study indicators includes laboratory tests (complete blood count, blood biochemistry, and urinalysis), pulmonary function tests (FVC, DLco, FEV1), 6MWT, 12-lead ECG, physical examination, vital signs, and the St. George's Respiratory Questionnaire (SGRQ). During the study, researchers should closely observe and supervise participants to ensure they complete the required treatments and examinations / assessments according to the study protocol. If any examination / assessment is deemed unacceptable due to quality issues, it should be repeated.

[0302] (1) Routine laboratory tests

[0303] The laboratory tests include the following items:

[0304] - Complete blood count: white blood cell count, white blood cell differential (basophil count and percentage, eosinophil count and percentage, neutrophil count and percentage, lymphocyte count and percentage, monocyte count and percentage), red blood cell count, hematocrit, hemoglobin, platelet count;

[0305] - Blood biochemistry: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin, direct bilirubin, total protein, albumin, blood urea nitrogen (BUN), uric acid (UA), potassium (K), sodium (Na), magnesium (Mg), phosphorus (P), creatinine (Cr), total cholesterol, triglycerides, gamma-glutamyl transferase, creatine phosphokinase, blood glucose, myoglobin, cystatin C, and eGFR (eGFR) estimated by serum cystatin C. eGFR estimated by cystatin C was calculated using the CKD-EPI formula.

[0306] - Urinalysis: urine pH, specific gravity, epithelial cells, casts, crystals, urine protein, urine glucose, ketone bodies, red blood cells, white blood cells;

[0307] - Blood pregnancy test for women of childbearing age;

[0308] - Urine pregnancy test for women of childbearing age;

[0309] - Coagulation function tests: plasma prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), D-dimer, international normalized ratio (INR) (optional);

[0310] -C-reactive protein (CRP);

[0311] - Platelet glycoprotein-specific autoantibodies (optional): anti-GPⅠb, anti-GPⅠX, anti-GPⅡb, anti-GPⅢa, anti-GMP140;

[0312] - Reticulocytes (optional);

[0313] - Thyroid function (optional): Total T3, Total T4, Free T3, Free T4, Thyroid-stimulating hormone;

[0314] - Anti-thyroid antibodies (optional): Thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TGAb), anti-thyroid receptor antibody (TRAb);

[0315] In addition to the laboratory tests required by the research process, researchers are responsible for conducting additional and more frequent clinical laboratory tests based on the clinical condition of the subjects.

[0316] (2) High-resolution CT scan

[0317] If the HRCT results obtained prior to screening meet the requirements for center review and evaluation, and are obtained within the 12 months prior to screening, the HRCT scan results can be used as evidence of eligibility for inclusion. All HRCT electronic scan results of the subjects will be stored at each research center and sent to the center for review and evaluation via confidential electronic transmission. The HRCT scan results must be reviewed and evaluated by qualified center review and evaluation experts (radiologists with extensive experience in diagnosing IPF).

[0318] (3) Pathological evaluation of lung surgical biopsy

[0319] If the patient has a pathological evaluation result from a surgical lung biopsy within the 5 years prior to screening, the histopathological criteria must meet the 2022 ATS / ERS / JRS / ALAT guidelines, standard 1. Similar to HRCT scan results, pathological slides must also be professionally assessed by qualified central review and evaluation experts (pathologists with extensive experience in IPF diagnosis).

[0320] (4) Lung volume / respiratory volume measurement

[0321] Lung volume / respiratory capacity measurements include assessments of forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and carbon monoxide diffusing capacity (DLco).

[0322] • Vital capacity assessment includes evaluation of FVC and FEV1, with screening measured before and after bronchodilator inhalation, respectively. The inclusion criteria specify the range of %FVC before bronchodilator use.

[0323] • DLco measurement is used to assess the lungs' ability to diffuse / transport carbon monoxide. DLco measurement must occur before the 6-minute walk test.

[0324] All collected FVC, FEV1, and DLco data will be recorded in detail in the database and integrated into the clinical research database.

[0325] Quality control standards for FVC inspection:

[0326] 1) Standard for the onset of exhalation: There is no hesitation at the start of exhalation, and it is explosive. The F-V curve shows the appearance of the PEF peak.

[0327] 2) Criteria for termination of exhalation: ① The subject cannot continue to exhale. Although subjects should be encouraged to exhale to their maximum capacity, the test should be stopped immediately if the subject experiences discomfort or fainting, and the subject should be protected from falling. ② The exhalation time is ≥6s, or the T-V curve shows an expiratory plateau (volume change <0.025L) lasting for more than 1s.

[0328] 3) Acceptable expiratory criteria: ① Satisfactory start criteria; ② No coughing in the first second of expiration, with a smooth curve and no subsequent coughing that affects the results; ③ Satisfactory end criteria; ④ No glottal closure; ⑤ No air leakage; ⑥ No teeth or tongue obstructing the mouthpiece; ⑦ No re-inhalation during expiration. An acceptable curve must meet all of the above conditions.

[0329] 4) Repeatability: Measure three times. In three acceptable tests, the difference between the best and second-best values ​​of FVC and FEV1 should be ≤0.150L. If FVC ≤1.000L, the difference should be ≤0.100L. Overlapping F-V and T-V curves can be printed. If the curves overlap, the repeatability is good; otherwise, the repeatability is not ideal. Unacceptable tests should be discarded before evaluating repeatability and cannot be used to determine the maximum value. If all three tests fail to meet the standard, the test should be repeated, but usually not exceeding eight times. In individuals with high airway reactivity, repeated forced breathing may induce airway spasm, resulting in a progressive decrease in respiratory volume and flow, making repeatability impossible. This should be stated in the report.

[0330] Selection of FVC and FEV1 test results: Both FVC and FEV1 are taken as the maximum values ​​among all tests that meet the acceptable criteria, and can come from different tests. The curve with the largest sum of FVC and FEV1 is the optimal test curve.

[0331] (5) 6-minute walk test

[0332] The 6-minute walk test (6MWT) measures the distance a patient can walk independently on flat ground within 6 minutes. The 6MWT is a comprehensive assessment tool for evaluating the overall bodily system status during walking. It has been established as one of the assessment methods for walking tests in cardiopulmonary diseases, and its results show correlation with physiological measurements and disease severity.

[0333] The Borg Scale, as part of the 6MWT testing process, is a patient-administered assessment tool.

[0334] (6) St. George's Respiratory Questionnaire (SGRQ)

[0335] The St. George Respiratory Questionnaire (SJQ) is a standardized patient self-report questionnaire used to quantify the degree of impairment in quality of life associated with respiratory diseases. It is designed to compare and measure the health status of patients with respiratory impairment to reflect the impact on health-related quality of life (HRQL) and to quantify changes in health status before and after treatment. The St. George Respiratory Questionnaire has demonstrated good cross-sectional and longitudinal accuracy and validity in assessing IPF patients.

[0336] The SGRQ comprises 50 assessment items, divided into two parts and three categories: Symptoms (8 items), Activities (16 items), and Impact on Life (26 items). Each item has an experience-based weighted score, and each category ranges from 0 to 100 points. The total score for the entire questionnaire is calculated. Higher scores have a greater impact on HRQL. During the study visit, the SGRQ must be completed before all non-PRO assessments and before the subject receives any information about their disease state or begins treatment.

[0337] (7) Physical examination and vital signs

[0338] A complete physical examination includes an examination of all bodily systems: height, weight, skin, head and neck, mouth, chest, abdomen, lymph nodes, nerves and psychiatry, limbs and other parts.

[0339] Vital signs checks include: sitting blood pressure, pulse, respiratory rate, body temperature, and blood oxygen saturation;

[0340] (8) Survival status assessment

[0341] Throughout the study, the participants' survival status should be tracked and assessed until they withdraw from the study or are lost to follow-up. If necessary, survival assessments can be conducted remotely (via telephone or other remote methods), but these communications must be strictly documented in the original files. The recommended procedure is as follows:

[0342] i. If the subject is unable to provide information about their survival status, their authorized family member or representative may be contacted.

[0343] ii. If a subject receives a lung transplant, information such as the date and time of the transplant, the specific details of the transplant, the specific admission date, and the current condition should be collected (patients who receive lung transplants must withdraw from this study at the same time).

[0344] iii. If a subject dies, the specific date and time of death, details of death, and cause of death will be recorded in detail. This information may be obtained from the subject's authorized representative or family member.

[0345] iv. If a participant is lost to follow-up, obtain their survival status through the relevant regulatory agency if feasible.

[0346] (9) 12-lead electrocardiogram assessment

[0347] The 12-lead ECG assessment during the screening period should occur before the use of bronchodilators, or not on the same day.

[0348] 5.6 Results of Phase II Clinical Trial

[0349] 5.6.1 Trial population

[0350] Patients aged 40 to 80 years (inclusive) with a confirmed clinical and radiographic diagnosis of IPF, and meeting the criteria of %FVC ≥50% and ≤90%, and %DLco ≥30% and ≤90%. 54 patients were enrolled in the first phase of the study, and 54 patients were enrolled in the second phase (24 in the 300mg group, 23 in the 400mg group, and 7 in the placebo group).

[0351] At baseline, patients primarily had mild to moderate disease. The mean age of patients was 65.5 (6.44) years, and the majority (93 / 108 [86.1%]) were male. At baseline, demographic characteristics, duration of IPF diagnosis, lung function, and health-related quality of life were similar across groups (Table 4).

[0352] Table 4. Demographic and Baseline Clinical Characteristics

[0353] 5.6.2 Security

[0354] By week 24 of treatment, 56.6% of the subjects in this study experienced at least one AK3280-related treatment-adverse event (TEAE), most of which were grade 1 or 2, and all dose groups showed good tolerability.

[0355] Table 2 summarizes drug-related treatment-associated adverse events (TEAEs) with an incidence ≥10% in any treatment group. Ranked by the total incidence in the AK3280 group, the AK3280-related TEAEs were: rash (8.4%), elevated aspartate aminotransferase (8.4%), elevated alanine aminotransferase (8.4%), decreased platelet count (8.4%), decreased glomerular filtration rate (8.4%), elevated serum creatine phosphokinase (6.0%), elevated gamma-glutamyl transferase (6.0%), elevated urinary β2-microglobulin (3.6%), and diarrhea (2.4%). In addition, the total incidence of AK3280-related treatment-related gastrointestinal disorders (including diarrhea, dyspepsia, nausea, abdominal distension, and flatulence TEAEs) was 13.3%.

[0356] Table 5 Summary of Treatment-Related Adverse Events (TEAEs) Classified by Preferred Terminology (Incidence ≥10% in any treatment group) 0-24 Weeks Double-Blind Period (Safety Analysis Set)

[0357] According to the product information for pirfenidone capsules from the domestic company Contini (2021), adverse reactions to pirfenidone were confirmed in 87.9% of IPF patients. The main adverse reactions (i.e., drug-related adverse events during treatment) and their corresponding incidence rates were photosensitivity (51.7%), loss of appetite (23.0%), gastrointestinal discomfort (14%), nausea (20.0%), and elevated gamma-glutamyl transferase (20.0%). In addition, the incidence of skin rashes other than photosensitivity exceeded 5%.

[0358] Table 6 Comparison of safety and tolerability of AK3280 and pirfenidone

[0359] *The preferred term refers to new adverse events occurring during treatment in patients receiving pirfenidone in the CAPACITY 004 and 006 studies (72-week follow-up) with an incidence of ≥5%.

[0360] The data in Table 3 show that AK3280 has superior safety and tolerability compared to pirfenidone. In this study, no common safety issues associated with pirfenidone, including gastrointestinal, central nervous system, respiratory, cardiovascular events, and phototoxicity, were observed when using AK3280.

[0361] Comparing the above data, it can be seen that the AK3280 has the following advantages in terms of security:

[0362] (1) In the AK3280 study, “rash” included photosensitivity. Compared with the pirfenidone data (photosensitivity + rash), the incidence of AK3280-related rash or photosensitivity (8.4%) was significantly lower than that of pirfenidone (≥51.7%).

[0363] (2) The incidence of gastrointestinal adverse reactions related to AK3280 (13.3%) was lower than that of pirfenidone (≥23.0%).

[0364] (3) The incidence of elevated γ-glutamyl transferase associated with AK3280 (6.0%) was lower than that of pirfenidone (≥20.0%), suggesting that AK3280 is less likely to cause hepatocellular damage.

[0365] 5.6.3 Treatment Efficacy

[0366] Regarding efficacy, the results showed that after 24 weeks of continuous treatment, the mean least-squares difference in the change in pulmonary function index (FVC) from baseline in the 300 mg BID group compared to the placebo group was 85.6 mL (95% CI: -47.1–218.3 mL), and the adjusted %pFVC difference was 3.3% (95% CI: -1.0%–7.5%). The 400 mg BID group showed even more significant differences in changes in major pulmonary function indicators compared to the placebo group, with statistically significant differences in both FVC and adjusted %pFVC from baseline compared to the placebo group, with mean least-squares values ​​of 209.4 mL (95% CI: 76.1–342.6 mL) [p = 0.002] (Figure 12, changes in FVC from baseline at different doses) and 6.4% (95% CI: -1.0%–7.5%). CI: 2.1%–10.7% [p = 0.004] (Figure 13, changes in %pFVC from baseline at different doses). Furthermore, compared to the placebo group, subjects in the AK3280 400mg BID group showed a sustained decrease in their St. George's Respiratory Questionnaire (SGRQ) scores over 24 weeks of continuous treatment, with a decrease of 4.1 points from baseline at week 12 and a decrease of 6.2 points from baseline at week 24, reaching the minimum clinically significant difference for SGRQ improvement (Figure 14, changes in SGRQ scores from baseline at different doses). The six-minute walk test (6MWT) results showed that in the high-dose AK3280 group, the proportions of subjects with a 6MWT reduction of more than 50m at week 24 were 16.7% (i.e., a reduction of 15.3%) in the 300mg BID group and 8.7% (i.e., a reduction of 23.3%) in the 400mg BID group, compared to 32% in the placebo group. This indicates that the proportion of subjects with a 6MWT reduction of more than 50m in the high-dose AK3280 group was significantly lower than that in the placebo group. With increasing AK3280 dose, the proportion of patients with a 6-minute walk test distance reduction ≥50m from baseline or who died decreased. The two high-dose groups reduced the likelihood of deterioration ≥25m and ≥50m or death by nearly 2-fold and 4-fold, respectively (Figure 15, change in six-minute walk distance from baseline at different doses). Currently marketed drugs for treating IPF include pirfenidone and nintedanib, both of which only delay the decline in FVC. However, the AK3280 data above showed that the high-dose group, especially the AK3280 400mg BID dose group, achieved an increase in FVC of 209.4 mL from baseline, and an adjusted %pFVC improvement of 6.4% from baseline, demonstrating the potential to improve lung function and reverse disease progression (see Table 7, comparison of FVC results between AK3280 and marketed drugs). Therefore, AK3280 has a significant clinical advantage over marketed drugs.

[0367] Table 7 Comparison of forced vital capacity (FVC) results between AK3280 and marketed drugs in patients with idiopathic pulmonary fibrosis (IPF).

[0368] FVC results for pirfenidone, nintedanib, and namistrazepoxide are from sources 1-3, as shown below:

[0369] [1] InterMune Inc. (pirfenidone capsules).Statistical Review.FDA,October 2014,https: / / www.accessdata.fda.gov / drugsatfda_docs / nda / 2014 / 022535Orig1s000StatR.pdf.Accessed March 13,2026.

[0370] [2]Richeldi L, et al., 2014. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis[J]. New England Journal of Medicine, 370(22):2071-2082.

[0371] [3]Richeldi L, et al. Nerandomilast in patients with idiopathic pulmonary fibrosis. N Engl J Med 2025;392:2193–2202.

[0372] It should be understood that the above embodiments are exemplary and are not intended to encompass all possible implementations included in the claims. Various modifications and changes can be made to the above embodiments without departing from the scope of this disclosure. Similarly, the various technical features of the above embodiments can be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only illustrate several implementations of the present invention and do not limit the scope of protection of this patent.

Claims

1. Use of Compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of interstitial lung disease (ILD), comprising administering to a subject in need thereof a pharmaceutical composition comprising Compound I or a pharmaceutically acceptable salt thereof, the administration of Compound I being at a total daily dose of 200-1000 mg; 2. Use according to claim 1, characterized in that, It is selected from one or more of the following conditions: (1) The total daily dose is 200-800 mg, 400-800 mg or 600-800 mg; (2) The total daily dose is administered once, twice, or three times a day; (3) The total daily dose is 600 or 800 mg, administered in two equal doses; (4) The duration of administration of the total daily dose includes the first treatment period and / or the second treatment period; (5) The people in need are adults aged 40-80; (6) The dosage form of the pharmaceutical composition is powder, pill, tablet, capsule, oral liquid, aerosol or injection; (7) The application reverses, prevents, delays, or slows the progression of respiratory impairment in the person in need; (8) The interstitial lung disease includes non-progressive fibrotic interstitial lung disease and progressive fibrotic interstitial lung disease; the progressive fibrotic interstitial lung disease is, for example, idiopathic pulmonary fibrosis and PPF; the non-progressive fibrotic interstitial lung disease is, for example, hypersensitivity pneumonitis and non-fibrotic NSIP.

3. Use according to claim 1 or 2, characterized in that, It is selected from one or more of the following conditions: (1) The total daily dose is administered twice a day; (2) The dosage form of the pharmaceutical composition is a tablet; (3) The first treatment period is at least 24 weeks; (4) The second treatment period is at least 24 weeks; (5) The application includes administration of a total daily dose selected from the group consisting of 200 mg, 400 mg, 600 mg and 800 mg during the first treatment period; (6) The application includes administration of a total daily dose selected from the group consisting of 400 mg, 600 mg and 800 mg during the second treatment period; (7) The progression of the respiratory function impairment was determined by measuring changes in forced vital capacity (FVC) and / or percentage predicted forced vital capacity (%pFVC) during the first and / or second treatment periods.

4. The application according to any one of claims 1-3, characterized in that, Compared to before treatment, the application improved at least one symptom selected from the following groups: forced vital capacity (FVC), percentage predicted forced vital capacity (%pFVC), carbon monoxide diffusion capacity (DLco), St. George's Respiratory Questionnaire score (SGRQ), and 6-minute walk test distance (6MWT).

5. The application according to any one of claims 1-4, characterized in that, During the first treatment period of at least 24 weeks, the application increased forced vital capacity and / or percentage predicted forced vital capacity (%pFVC) compared to before treatment.

6. The application according to any one of claims 1-5, characterized in that, During the first treatment period of at least 24 weeks, the application of a total daily dose of 800 mg, compared to before treatment, increased forced vital capacity and / or percentage predicted forced vital capacity (%pFVC).

7. The application according to any one of claims 1-6, characterized in that, The application increases the %pFVC value by at least 2%, preferably at least 4%, and more preferably at least 6%.

8. The application according to any one of claims 1-7, characterized in that, During the first treatment period of at least 24 weeks, the application of a total daily dose of 600 mg, compared to before treatment, increased forced vital capacity and / or percentage predicted forced vital capacity (%pFVC).

9. The application according to any one of claims 1-8, characterized in that, The application increases the %pFVC value by at least 1%, preferably at least 2%, and more preferably at least 3%.

10. The application according to any one of claims 1-9, characterized in that, It is selected from one or more of the following conditions: (1) During the first treatment period of at least 12 weeks, the application reduced the St. George Respiratory Questionnaire (SGRQ) score compared to before treatment. (2) During the first treatment period of at least 12 weeks, the application of a total daily dose of 800 mg, compared with the pre-treatment dose, resulted in a reduction of at least 2, 3 or 4 points in the St. George Respiratory Questionnaire (SGRQ) score; (3) During the first treatment period of at least 24 weeks, the application reduced the St. George Respiratory Questionnaire (SGRQ) score compared to before treatment. (4) During the first treatment period of at least 24 weeks, the application of a total daily dose of 800 mg, compared with the pre-treatment dose, resulted in a St. George's Respiratory Questionnaire (SGRQ) score of at least 4, at least 5, or at least 6. (5) During the first treatment period of at least 24 weeks, the application reduced the rate of 6MWT worsening compared to before treatment, or the application reduced the rate of 6MWT decline by more than 50m. (6) During the first treatment period of at least 24 weeks, a total daily dose of 600 mg was administered, and the proportion of 6MWT reductions exceeding 50 m compared to the pre-treatment period was reduced to less than 20%, less than 18%, or less than 17%.

11. The application according to any one of claims 1-10, characterized in that, During the first treatment period of at least 24 weeks, a total daily dose of 800 mg was administered, and the proportion of 6MWT decreases by more than 50 m compared to before treatment was reduced to less than 15%, less than 12%, or less than 10%.

12. The application according to any one of claims 1-11, characterized in that, It is selected from one or more of the following conditions: (1) The application shows a reduction in at least one adverse event selected from the group consisting of: rash, photosensitivity, nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, loss of appetite, constipation, headache, dizziness, drowsiness, fatigue, drug intolerance, elevated AST, ALT, GGT and hepatotoxicity. (2) The application demonstrates a reduction in at least one gastrointestinal-related adverse event selected from the group consisting of: nausea, vomiting, abdominal pain or bloating, indigestion, diarrhea, decreased appetite, and constipation; (3) The application showed a reduction in at least one neurological-related adverse event selected from the group consisting of headache, dizziness, and somnolence; (4) The application showed a reduction in at least one liver function-related adverse event selected from the group consisting of: elevated AST, ALT, GGT and hepatotoxicity; (5) The application demonstrates a reduction in at least one skin-related adverse event selected from the group consisting of: rash and photosensitivity.

13. The application according to any one of claims 1-12, characterized in that, Those in need must meet the following criteria before starting treatment: %FVC ≥ 50% and ≤ 90%, %DLco ≥ 30% and ≤ 90%.

14. The application according to any one of claims 1-13, characterized in that, The pharmaceutical composition is administered orally.